Volume 4, Issue 1 pp. 30-36
ORIGINAL ARTICLE

Locating the source of hyperglycemia: Liver versus muscle

Haoyong YU

Haoyong YU

Department of Endocrinology and Metabolism, Shanghai Clinical Center for Diabetes, Shanghai Jiaotong University Affiliated Sixth People’s Hospital, Shanghai Diabetes Institute, Shanghai Key Laboratory of Diabetes Mellitus, Shanghai, China

Search for more papers by this author
Dequan ZHOU

Dequan ZHOU

Endocrine Research Unit, Division of Endocrinology, Diabetes, Metabolism and Nutrition, Mayo Foundation, Rochester, Minnesota, USA

Search for more papers by this author
Weiping JIA

Weiping JIA

Department of Endocrinology and Metabolism, Shanghai Clinical Center for Diabetes, Shanghai Jiaotong University Affiliated Sixth People’s Hospital, Shanghai Diabetes Institute, Shanghai Key Laboratory of Diabetes Mellitus, Shanghai, China

Search for more papers by this author
ZengKui GUO

ZengKui GUO

Endocrine Research Unit, Division of Endocrinology, Diabetes, Metabolism and Nutrition, Mayo Foundation, Rochester, Minnesota, USA

Search for more papers by this author
First published: 10 November 2011
Citations: 6
ZengKui Guo, 5-194 Joseph, Mayo Foundation, Rochester, MN 55905, USA.
Tel: +1 507 255 6461
Fax: +1 507 255 4828
Email: [email protected]

Abstract

Background: Glucose homeostasis relies on insulin to suppress hepatic glucose production and to stimulate glucose uptake by peripheral tissues (primarily skeletal muscle) during and after a meal or glucose load. Glucose metabolism impairments in the liver and/or muscle attenuate these insulin actions, causing hyperglycemia. Thus, identifying the loci of the impairments can improve the understanding of hyperglycemia and enable organ-targeted interventions.

Methods: Studies were performed to identify such loci using modified oral glucose tolerance test (OGTT) techniques in individuals with type 2 diabetes (T2D) and overweight/obese individuals.

Results: Individuals with severe T2D were found to have significantly impaired glucose metabolism in both the liver and muscle. In contrast, impairments in glucose metabolism in individuals with non-severe T2D were predominantly localized in the liver or muscle, but not both. Similarly, milder impairments in overweight or obese individuals were clearly localized in either the liver or muscle, but not both. All these impairments are quantifiable.

Conclusion: Impairments in glucose metabolism in the liver and muscle can be differentiated and quantified in a clinical setting.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.